The effect of Lipacreon on the postoperative weight loss and the fecal consistency in patients after gastrectomy for gastric cancer

The effect of Lipacreon on the postoperative weight loss and the fecal consistency in patients after gastrectomy for gastric cancer - The effect of Lipacreon on the postoperative weight loss and the fecal consistency in patients after gastrectomy for gastric cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000012796

Enrollment

Registered

2014-02-01

Start date

2014-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients after gastrectomy for gastric cancer

Interventions

Oral Administration of Lipacreon at every meal for a year

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1 the patients after gastrectomy for histologically confirmed gastric cancer without recurrence and except for stage IV 2 over 20 years old 3 performance status 0-2(ECOG scale) 4 informed consent 5 disorder of pancreas exocrine function for PFD test

Exclusion criteria

Exclusion criteria: 1 active double cancer 2 severe or uncontrollable complication 3 decompensated chronic pancreatitis 4 after pancrectomy 5 cystic fibrosis 6 gout 7 allergy to pancrelipase 8 allergy to proteins of pig 9 pregnancy 10 the patients judged as unsuitable for the study

Design outcomes

Primary

Measure	Time frame
effect on postoperative wight loss after gastrectomy	—

Secondary

Measure	Time frame
effect on fecal consistency adverse event	—

Countries

Japan

Contacts

Public ContactKatsuyoshi kudoh

Tohoku University Graduate School of Medicine Division Of Biological Regulation and Oncology

kykudo@surg1.med.tohoku.ac.jp0227177205

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026